| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d91994553cbc292b5baf2e86fe604ba8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5256
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24143 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-012 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-002 |
| filingDate |
2008-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d236c35637f01460b2cb1390958acf3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_736c227fca08538c0bcde29c9932e434
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b95cfe8ce465c5cbba35f3cbb86813f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_88a44e0be63d5b8f136046119095967e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e36ef7064ec7f87896c7482c6eee5184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f62c6dffa14bb6f5d24fc7e0b8bdd07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e16118dc06a429b93d8749d139fcca3 |
| publicationDate |
2016-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3081231-A2 |
| titleOfInvention |
Utilization of recombinant influenza viruses and modified vaccinia ankara virus (mva) with genes that encode for the toxoplasma gondii sag1 and sag2 surface proteins, as vaccines against toxoplasmosis |
| abstract |
The present invention concerns to recombinant influenza viruses and modified vaccinia Ankara viruses (MVA), and to a process for construction of recombinant influenza viruses and modified vaccinia Ankara viruses (MVA) with genes that encode for the T. gondii parasite SAG1 (MVA) and SAG2 (MVA and influenza) proteins, by means of a homologous recombination technique between two transfer vectors (for construction of MVA virus) and reverse genetics (for construction of influenza virus). Additionally, the present invention describes a vaccine composition using recombinant influenza viruses and modified vaccinia Ankara viruses (MVA), or recombinant adenoviruses and modified vaccinia Ankara viruses (MVA), for immunization against infections caused by the T. gondii parasite. n Finally, the present invention describes a novel immunization method against infections or tumoral diseases, using recombinant influenza virus and adenovirus, in heterologous protocols of immune response induction and enhancement. |
| priorityDate |
2007-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |